Alendronic Acid
Also known as: Alendronate, Fosamax, alendronate sodium
A bisphosphonate used to prevent and treat osteoporosis, particularly in postmenopausal women. First-line pharmacological approach for osteoporosis alongside calcium and vitamin D. Reduces the risk of vertebral and hip fractures. Taken as a weekly oral tablet with specific administration requirements.
This page contains self-reported experiences from the Narrated community — not clinical data. Outcomes are subjective. Always consult your doctor or specialist before starting, stopping, or changing any approach.
Regulatory status is factual context, not a clinical-risk assessment. Laws vary by country.
Community Experiences
0 reports from women who tried Alendronic Acid
No one has reported on this approach yet.
Be the first to share an experience.
Research Context
Research context compiled from published sources
How does Alendronic Acid work?
Binds to hydroxyapatite in bone, inhibiting osteoclast-mediated bone resorption. Osteoclasts take up the bisphosphonate during bone resorption and undergo apoptosis. This shifts the balance of bone remodelling in favour of osteoblast-mediated bone formation, increasing bone mineral density over time.
Research Depth
Well Studied
Extensive human research over many years, including randomized controlled trials.
Long-Term Evidence
Well Characterized
Decades of long-term human-use data are available.
Known Interactions
Reported Contraindicated Populations
Published Dose Ranges
Dose ranges from published research. Individual dosing is context-specific and belongs in a healthcare conversation.
Factual research context from published sources — not a clinical-risk assessment or guidance. Research classifications may change as new data emerges.
Related Approaches
Other approaches tracked on Narrated.
Data last updated: No data yet